tradingkey.logo
怜玢
マヌケット
ニュヌス
分析
ツヌル


English
繁䜓䞭文
à¹„àž—àž¢
Tiếng việt
简䜓䞭文
Español
Português
Deutsch
한국얎
日本語

tradingkey.logo
怜玢



Adaptimmune Therapeutics PLC

ADAP
0.055USD
0.0000.00%
終倀 03/30, 16:00ET15分遅れの株䟡
87.31M時䟡総額
損倱額盎近12ヶ月PER


Adaptimmune Therapeutics PLC

0.055
0.0000.00%
抂芁金融分析䌁業名

抂芁

金融

分析

䌁業名

詳现情報 Adaptimmune Therapeutics PLC 䌁業名

Adaptimmune Therapeutics PLC is focused on pre-clinical programs, including PRAME and CD70-directed T-cell therapies, and its allogeneic pipeline. PRAME is highly expressed across a range of solid tumors, including ovarian, endometrial, lung and breast cancers. The CD70 program targets the CD70 antigen, which is expressed across a range of hematological malignancies (acute myeloid leukemia and lymphoma) and solid tumors (renal cell carcinoma). It is using TRuC technology to develop a T-cell therapy (ADP-520) against CD70, with membrane bound IL-15 to enhance persistence. ADP-520 is in pre-clinical testing. TRuC technology combines the targeting of CAR-T cells with T-cell TCR signaling.

Adaptimmune Therapeutics PLCの䌁業情報


䌁業コヌドADAP
䌚瀟名Adaptimmune Therapeutics PLC
䞊堎日May 06, 2015
最高経営責任者「CEO」Rawcliffe (Adrian George)
埓業員数506
蚌刞皮類Depository Receipt
決算期末May 06
本瀟所圚地60 Jubilee Avenue
郜垂ABINGDON
蚌刞取匕所NASDAQ Capital Market Consolidated
囜United Kingdom
郵䟿番号OX14 4RX
電話番号441235430000
りェブサむトhttps://www.adaptimmune.com/
䌁業コヌドADAP
䞊堎日May 06, 2015
最高経営責任者「CEO」Rawcliffe (Adrian George)

Adaptimmune Therapeutics PLCの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
611.22K
+65.65%
Mr. Lawrence M. (Larry) Alleva, CPA
Mr. Lawrence M. (Larry) Alleva, CPA
Non-Executive Independent Director
Non-Executive Independent Director
23.89K
--
Mr. Adrian Rawcliffe
Mr. Adrian Rawcliffe
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. William C. (Bill) Bertrand, Jr., Esq.
Mr. William C. (Bill) Bertrand, Jr., Esq.
Chief Operating Officer
Chief Operating Officer
--
--
Mr. John P. Furey
Mr. John P. Furey
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Kristen M. Hege, M.D.
Dr. Kristen M. Hege, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Andrew Allen, M.D., Ph.D.
Dr. Andrew Allen, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Priti Hegde, Ph.D.
Dr. Priti Hegde, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
611.22K
+65.65%
Mr. Lawrence M. (Larry) Alleva, CPA
Mr. Lawrence M. (Larry) Alleva, CPA
Non-Executive Independent Director
Non-Executive Independent Director
23.89K
--
Mr. Adrian Rawcliffe
Mr. Adrian Rawcliffe
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. William C. (Bill) Bertrand, Jr., Esq.
Mr. William C. (Bill) Bertrand, Jr., Esq.
Chief Operating Officer
Chief Operating Officer
--
--

収益内蚳

䌚瀟から関連デヌタがただ開瀺されおいたせん。
䌚瀟から関連デヌタがただ開瀺されおいたせん。
事業別
地域別
䌚瀟から関連デヌタがただ開瀺されおいたせん。

株䞻

曎新時刻: Sun, Mar 29
曎新時刻: Sun, Mar 29
株䞻統蚈
皮類
株䞻統蚈
株䞻統蚈
比率
Alpha Architect, LLC
0.30%
Menzel (Garry E)
0.23%
Rathbones Investment Management Limited
0.16%
Rawcliffe Adrian
0.15%
XTX Markets LLC
0.13%
他の
99.02%
株䞻統蚈
株䞻統蚈
比率
Alpha Architect, LLC
0.30%
Menzel (Garry E)
0.23%
Rathbones Investment Management Limited
0.16%
Rawcliffe Adrian
0.15%
XTX Markets LLC
0.13%
他の
99.02%
皮類
株䞻統蚈
比率
Individual Investor
0.63%
Investment Advisor
0.33%
Investment Advisor/Hedge Fund
0.21%
Venture Capital
0.13%
Research Firm
0.02%
他の
98.68%

機関投資家保有株


曎新時刻: Mon, Dec 8
曎新時刻: Mon, Dec 8
報告期間
機関投資家数
保有株匏数
比率
倉動額
2025Q4
165
42.25M
57.79%
-8.12K
2025Q3
183
42.26M
58.51%
-57.25M
2025Q2
189
116.07M
65.05%
-1.37M
2025Q1
186
117.46M
62.78%
-44.42M
2024Q4
186
127.90M
58.86%
-11.67M
2024Q3
189
154.60M
64.35%
-2.20M
2024Q2
192
156.54M
67.34%
-7.97M
2024Q1
203
164.83M
67.18%
-6.80M
2023Q4
199
145.59M
71.95%
-5.54M
2023Q3
217
150.77M
70.44%
+3.59M
詳现を芋る

株䞻動向


䌚瀟名
保有株匏数
比率
倉動額
倉動率
日付
Alpha Architect, LLC
800.00K
0.3%
--
--
Sep 30, 2025
Menzel (Garry E)
611.22K
0.23%
+401.29K
+191.15%
Apr 11, 2025
Rathbones Investment Management Limited
432.82K
0.16%
--
--
Sep 30, 2025
Rawcliffe Adrian
395.23K
0.15%
+219.59K
+125.03%
Apr 11, 2025
Bertrand William C Jr
198.89K
0.07%
+59.86K
+43.05%
Apr 11, 2025
Lunger (John)
170.89K
0.06%
+59.86K
+53.91%
Apr 11, 2025
Norry (Elliot)
133.26K
0.05%
+66.41K
+99.32%
Apr 11, 2025
Piccina (Cintia)
111.07K
0.04%
+94.24K
+559.70%
Apr 11, 2025
詳现を芋る

関連ETF


曎新時刻: Sat, Dec 6
曎新時刻: Sat, Dec 6
銘柄名
比率
ActivePassive International Equity ETF
0%
Fidelity Enhanced Small Cap ETF
0%
SPDR S&P International Small Cap ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
SPDR Portfolio Developed World ex-US ETF
0%
ActivePassive International Equity ETF
比率0%
Fidelity Enhanced Small Cap ETF
比率0%
SPDR S&P International Small Cap ETF
比率0%
Invesco NASDAQ Future Gen 200 ETF
比率0%
SPDR Portfolio Developed World ex-US ETF
比率0%

配圓金


過去5幎間の配圓金総支払額は 0.00 米ドルである。
日付
配圓金
暩利確定日
支払日
配圓萜ち日
デヌタなし

株匏分割


日付
配圓萜ち日
皮類
比率
デヌタなし
日付
配圓萜ち日
皮類
比率
デヌタなし
KeyAI
î™